drugset

drugset / Trial / NCT05200364

A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

NCT05200364 ↗

Phase 1 Terminated 58 enrolled Sutro Biopharma, Inc.

NaSequentialOpen-labelTreatment

Summary

Phase 1 trial to study the safety, pharmacokinetic and Preliminary Efficacy of STRO-002 in combination with Bevacizumab.

Timeline

Start: 2022-03-22
Primary completion: 2025-06-01
Completion: 2025-06-01

Publications

Li X, Zhou S, Abrahams CL, Krimm S, Smith J, Bajjuri K, Stephenson HT, Henningsen R, Hanson J, Heibeck TH, Calarese D, Tran C, Yin G, Stafford RL, Yam AY, Kline T, De Almeida VI, Sato AK, Lupher M, Bedard K, Hallam TJ. Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers. Mol Cancer Ther. 2023 Feb 1;22(2):155-167. doi: 10.1158/1535-7163.MCT-22-0322.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Luveltamab tazevibulin	Monoclonal antibody	—	Intravenous
Background	Bevacizumab	Monoclonal antibody	15 mg/kg	Intravenous

Indications